Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient (COMBAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00826644
Recruitment Status : Unknown
Verified January 2012 by In-Jae, Oh, MD, Chonnam National University Hospital.
Recruitment status was:  Recruiting
First Posted : January 22, 2009
Last Update Posted : January 10, 2012
Chong Kun Dang Pharmaceutical
Information provided by (Responsible Party):
In-Jae, Oh, MD, Chonnam National University Hospital

Brief Summary:

Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer.

Primary endpoints

  • to assess Response Rate

Secondary endpoints

  • to assess Overall response duration, Time to progression, Overall survival

Condition or disease Intervention/treatment Phase
Carcinoma, Small Cell Drug: Belotecan/Cisplatin Drug: Etoposide/Cisplatin Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer
Study Start Date : January 2009
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Belotecan Drug: Belotecan/Cisplatin
Belotecan : 0.5mg/㎡/day for Day 1 to 4, Cisplatin : 60mg/㎡/day for Day 1.
Active Comparator: Etoposide Drug: Etoposide/Cisplatin
Etoposide : 100mg/㎡/day for Day 1 to 3, Cisplatin : 60mg/㎡/day for Day 1. Repeat next cycle at Day 22.

Primary Outcome Measures :
  1. To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer [ Time Frame: two years ]

Secondary Outcome Measures :
  1. to assess the overall response duration [ Time Frame: two years ]
  2. To assess the time to progression [ Time Frame: two years ]
  3. to assess the overall survival [ Time Frame: two years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ECOG Performance status 0~2(those with performance status 2 must have been stable with no deterioration over the previous 2 weeks)
  • Histologically or cytologically confirmed small cell lung cancer Patient without chemotherapy and radiotherapy
  • Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site
  • Life expectancy of at least 3 months
  • Provision of written informed consent

Exclusion Criteria:

  • As judged by the investigator, any evidence of severe or uncontrolled systemic disease
  • Serum bilirubin greater than 3 times the upper limit of reference range(ULRR)
  • Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT)greater than 2.5 times ULN if no demonstrable liver metastases (or > 5 times in presence of liver metastases)
  • Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
  • Pregnancy or breast-feeding women(women of child-bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy
  • Evidence of brain metastasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00826644

Contact: In-Jae Oh, M.D.,Ph.D. 82-61-379-7617
Contact: Kyu-Sik Kim, M.D.,Ph.D. 82-61-379-7615

Korea, Republic of
Chonnam National University Hwasun Hospital Recruiting
Hwasun-gun, Jeonnam, Korea, Republic of
Contact: In-Jae Oh, M.D.,Ph.D.    82-61-379-7617   
Sponsors and Collaborators
Chonnam National University Hospital
Chong Kun Dang Pharmaceutical
Principal Investigator: In-Jae Oh, M.D.,Ph.D. Chonnam National University Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: In-Jae, Oh, MD, Assistant Professor, Chonnam National University Hospital Identifier: NCT00826644     History of Changes
Other Study ID Numbers: CSCLC-0810
First Posted: January 22, 2009    Key Record Dates
Last Update Posted: January 10, 2012
Last Verified: January 2012

Keywords provided by In-Jae, Oh, MD, Chonnam National University Hospital:
Small cell lung cancer
Response rate

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Carcinoma, Small Cell
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Etoposide phosphate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors